{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:39:39Z","timestamp":1753889979679,"version":"3.41.2"},"reference-count":20,"publisher":"IMR Press","issue":"10","license":[{"start":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T00:00:00Z","timestamp":1664150400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Amgen Asia Holdings Limited, Hong Kong SAR, China","award":["RS190135"],"award-info":[{"award-number":["RS190135"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>Background: Elevated concentrations of low-density lipoprotein cholesterol (LDL-C) are an important cause of recurrent cardiovascular events. This study aimed to describe the distribution and achieved concentrations of LDL-C among patients with myocardial infarction (MI), percutaneous coronary intervention (PCI), stroke, or transient ischaemic attack (TIA) in Hong Kong. Methods: Patients with a lipid test from a public hospital were identified from the Clinical Database and Analysis Reporting System of the Hong Kong Hospital Authority. Among patients with an inpatient hospitalization for MI, PCI, stroke or TIA, between 2003 to 2016, the distribution of LDL-C levels and the number (%) of patients achieving an absolute concentration of LDL-C &lt;1.8 mmol\/L at baseline (in-hospital) and during 12 months after hospital discharge were described. Results: A total of 18417 patients were included (mean [SD] age, 70.0 [12.9] years; male, 60.3%), of which 3637 had MI, 4096 had PCI, and 10684 had stroke or TIA. At hospital discharge 12082 (65.6%) patients were prescribed statins, 690 (3.7%) were prescribed nonstatins, and 1849 (10.0%) achieved an LDL-C &lt;1.8 mmol\/L. Overall, 5654 (30.7%) patients did not have LDL-C result available within 12 months of discharge (MI, 605 [16.6%]; PCI, 432 [10.5%]; stroke or TIA, 4617 [43.2%]). Among the overall cohort, 4591 (24.9%) patients achieved an LDL-C &lt;1.8 mmol\/L during 12 months of follow-up (MI, 1288 [35.4%]; PCI, 1542 [37.6%]; stroke or TIA, 1761 [16.5%]). Improvements in achieved LDL-C were observed over time with a mean LDL-C 2.64 (0.92) mmol\/L and 20.0% of patients achieving an LDL-C &lt;1.8 mmol\/L in 2003 as compared with a mean LDL-C 1.86 (0.70) mmol\/L and 53.9% of patients achieving an LDL-C &lt;1.8 mmol\/L in 2016. Conclusions: In this single centre cohort study from Hong Kong, nearly half of patients with MI, PCI, or stroke in 2016 appear to qualify for intensification of lipid-modifying drug treatment in order to achieve a treatment goal of LDL-C &lt;1.8 mmol\/L. Further research is required in Hong Kong to assess contemporary management of LDL-C in a larger group of patients with established atherosclerotic cardiovascular disease.<\/jats:p>","DOI":"10.31083\/j.rcm2310327","type":"journal-article","created":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T01:42:10Z","timestamp":1664502130000},"source":"Crossref","is-referenced-by-count":0,"title":["Low-Density Lipoprotein Cholesterol Treatment Target Achievement in Patients with Myocardial Infarction, Percutaneous Coronary Intervention, or Stroke in Hong Kong"],"prefix":"10.31083","volume":"23","author":[{"given":"Joseph E","family":"Blais","sequence":"first","affiliation":[{"name":"Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, University of Hong Kong, Hong Kong SAR, China"},{"name":"School of Public Health, LKS Faculty of Medicine, University of Hong Kong, Hong Kong SAR, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent KC","family":"Yan","sequence":"first","affiliation":[{"name":"Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, University of Hong Kong, Hong Kong SAR, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaxi","family":"Zhao","sequence":"first","affiliation":[{"name":"Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, University of Hong Kong, Hong Kong SAR, China"},{"name":"Digital and Data Innovation, AstraZeneca Global R&D (China) Co, Ltd, 200000 Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celine SL","family":"Chui","sequence":"first","affiliation":[{"name":"School of Public Health, LKS Faculty of Medicine, University of Hong Kong, Hong Kong SAR, China"},{"name":"School of Nursing, LKS Faculty of Medicine, University of Hong Kong, Hong Kong SAR, China"},{"name":"Laboratory of Data Discovery for Health, Hong Kong Science Park, Sha Tin, Hong Kong SAR, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian CK","family":"Wong","sequence":"first","affiliation":[{"name":"Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, University of Hong Kong, Hong Kong SAR, China"},{"name":"Laboratory of Data Discovery for Health, Hong Kong Science Park, Sha Tin, Hong Kong SAR, China"},{"name":"Aston Pharmacy School, Aston University, B4 7ET Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chung Wah","family":"Siu","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Medicine, University of Hong Kong, Hong Kong SAR, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther W","family":"Chan","sequence":"first","affiliation":[{"name":"Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, University of Hong Kong, Hong Kong SAR, China"},{"name":"Laboratory of Data Discovery for Health, Hong Kong Science Park, Sha Tin, Hong Kong SAR, China"},{"name":"Department of Pharmacy, The University of Hong Kong-Shenzhen Hospital, 518000 Shenzhen, GuangDong, China"},{"name":"The University of Hong Kong Shenzhen Institute of Research and Innovation, 518000 Shenzhen, GuangDong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16242","published-online":{"date-parts":[[2022,9,26]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Danchin N, Almahmeed W, Al-Rasadi K, Azuri J, Berrah A, Cuneo CA, et al. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol Management Practice Study (ICLPS). European Journal of Preventive Cardiology. 2018; 25: 1087\u20131094.","DOI":"10.1177\/2047487318777079"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Reda A, Almahmeed W, Dobrecky-Mery I, Huang P, Juarez-Herrera U, Ranjith N, et al. A narrative review and expert panel recommendations on dyslipidaemia management after acute coronary syndrome in countries outside Western Europe and North America. Advances in Therapy. 2020; 37: 1754\u20131777.","DOI":"10.1007\/s12325-020-01302-4"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Navar AM, Matskeplishvili ST, Urina-Triana M, Arafah M, Chen JW, Sukonthasarn A, et al. Prospective evaluation of lipid management following acute coronary syndrome in non-Western countries. Clinical Cardiology. 2021; 44: 955\u2013962.","DOI":"10.1002\/clc.23623"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019; 139: e1082\u2013e1143.","DOI":"10.1161\/CIR.0000000000000624"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European Heart Journal. 2020; 41: 111\u201388.","DOI":"10.1093\/eurheartj\/ehz455"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine. 2015; 372: 2387\u20132397.","DOI":"10.1056\/NEJMoa1410489"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. New England Journal of Medicine. 2017; 376: 1713\u20131722.","DOI":"10.1056\/NEJMoa1615664"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. New England Journal of Medicine. 2018; 379: 2097\u20132107.","DOI":"10.1056\/NEJMoa1801174"},{"key":"ref9","unstructured":"Government of the Hong Kong Special Administration Region, Department of Health, Drug Office. Drug database [Internet]. 2020. Available at: https:\/\/www.drugoffice.gov.hk\/eps\/do\/en\/consumer\/search_drug_database.html (Accessed: 20 January 2022)."},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Wang Y, Yan BP, Nichol MB, Tomlinson B, Lee VWY. Real-world study of low-density lipoprotein cholesterol levels and cardiovascular outcomes in Chinese: a retrospective cohort study in post-percutaneous coronary intervention acute coronary syndrome patients. International Journal of Cardiology. 2017; 249: 18\u201324.","DOI":"10.1016\/j.ijcard.2017.07.016"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Sud M, Han L, Koh M, Abdel-Qadir H, Austin PC, Farkouh ME, et al. Low-density lipoprotein cholesterol and adverse cardiovascular events after percutaneous coronary intervention. Journal of the American College of Cardiology. 2020; 76: 1440\u20131450.","DOI":"10.1016\/j.jacc.2020.07.033"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Amarenco P, Bogousslavsky J, Callahan 3 A., Goldstein LB, Hennerici M, Rudolph AE, et al. High-dose atorvastatin after stroke or transient ischemic attack. New England Journal of Medicine. 2006; 355: 549\u201359.","DOI":"10.1056\/NEJMoa061894"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Amarenco P, Kim JS, Labreuche J, Charles H, Abtan J, B\u00e9jot Y, et al. A comparison of two LDL cholesterol targets after ischemic stroke. New England Journal of Medicine. 2020; 382: 9\u201319.","DOI":"10.1056\/NEJMoa1910355"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Szarek M, Amarenco P, Callahan A, DeMicco D, Fayyad R, Goldstein LB, et al. Atorvastatin reduces first and subsequent vascular events across vascular territories. Journal of the American College of Cardiology. 2020; 75: 2110\u20132118.","DOI":"10.1016\/j.jacc.2020.03.015"},{"key":"ref15","unstructured":"Government of the Hong Kong Special Administration Region, Census and Statistics Department. Hong Kong annual digest of statistics [Internet]. 2019. Available at: https:\/\/www.censtatd.gov.hk\/hkstat\/sub\/sp140.jsp?productCode=B1010003Edition (Accessed: 20 January 2022)."},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC\/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. Circulation. 2014; 129: S1\u201345.","DOI":"10.1161\/01.cir.0000437738.63853.7a"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Bohula EA, Morrow DA, Giugliano RP, Blazing MA, He P, Park J, et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology. 2017; 69: 911\u2013921.","DOI":"10.1016\/j.jacc.2016.11.070"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC\/EAS guidelines for the management of dyslipidaemias. European Heart Journal. 2016; 37: 2999\u20133058.","DOI":"10.1093\/eurheartj\/ehw272"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Danese MD, Gleeson M, Kutikova L, Griffiths RI, Khunti K, Seshasai SRK, et al. Management of lipid-lowering therapy in patients with cardiovascular events in the UK: a retrospective cohort study. BMJ Open. 2017; 7: e013851.","DOI":"10.1136\/bmjopen-2016-013851"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"De Luca L, Arca M, Temporelli PL, Meessen J, Riccio C, Bonomo P, et al. Current lipid lowering treatment and attainment of LDL targets recommended by ESC\/EAS guidelines in very high-risk patients with established atherosclerotic cardiovascular disease: Insights from the START registry. International Journal of Cardiology. 2020; 316: 229\u2013235.","DOI":"10.1016\/j.ijcard.2020.05.055"}],"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/23\/10\/10.31083\/j.rcm2310327","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T18:03:19Z","timestamp":1732730599000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/23\/10\/10.31083\/j.rcm2310327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,26]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022]]}},"alternative-id":["S1530-6550(22)00674-3"],"URL":"https:\/\/doi.org\/10.31083\/j.rcm2310327","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"type":"print","value":"1530-6550"},{"type":"electronic","value":"2153-8174"}],"subject":[],"published":{"date-parts":[[2022,9,26]]},"article-number":"327"}}